Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04213794

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (TOASTIT)

A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)

Sponsor: Mayo Clinic

Conditions Malignant Abdominal Neoplasm Malignant Pelvic Neoplasm Recurrent Colon Carcinoma Recurrent Desmoplastic Small Round Cell Tumor Recurrent Fallopian Tube Carcinoma Recurrent Gastric Carcinoma Recurrent Liposarcoma Recurrent Malignant Mesothelioma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Rectal Carcinoma Recurrent Rhabdomyosarcoma Recurrent Sarcoma Refractory Colon Carcinoma Refractory Desmoplastic Small Round Cell Tumor Refractory Fallopian Tube Carcinoma Refractory Gastric Carcinoma Refractory Liposarcoma Refractory Malignant Mesothelioma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma Refractory Rectal Carcinoma Refractory Rhabdomyosarcoma Refractory Sarcoma Resectable Liposarcoma Resectable Malignant Mesothelioma Resectable Sarcoma

Interventions Biospecimen Collection Cisplatin Computed Tomography Cytoreductive Surgery Doxorubicin Hyperthermic Intraperitoneal Chemotherapy Magnetic Resonance Imaging Positron Emission Tomography Sodium Thiosulfate

Updated 15 times since 2020 Last updated: Feb 18, 2025 Started: Nov 8, 2019 Primary completion: Mar 4, 2024 Completion: Oct 3, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow accrual

Other terminated trials from Mayo Clinic

See all terminations from Mayo Clinic

This EARLY_PHASE1 trial investigates Malignant Abdominal Neoplasm and Malignant Pelvic Neoplasm and is currently terminated or withdrawn. Mayo Clinic leads this study, which shows 15 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

15 versions recorded

Jun 2025 — Present [monthly]

Terminated EARLY_PHASE1
Mar 2025 — Jun 2025 [monthly]

Terminated EARLY_PHASE1

Status: Active Not Recruiting → Terminated
Sep 2024 — Mar 2025 [monthly]

Active Not Recruiting EARLY_PHASE1

Status: Recruiting → Active Not Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Mar 2024 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

▶ Show 10 earlier versions

Feb 2024 — Mar 2024 [monthly]

Recruiting EARLY_PHASE1
Jun 2023 — Feb 2024 [monthly]

Recruiting EARLY_PHASE1
Feb 2023 — Jun 2023 [monthly]

Recruiting EARLY_PHASE1
Jun 2022 — Feb 2023 [monthly]

Recruiting EARLY_PHASE1
May 2022 — Jun 2022 [monthly]

Recruiting EARLY_PHASE1
Apr 2022 — May 2022 [monthly]

Recruiting EARLY_PHASE1
Mar 2021 — Apr 2022 [monthly]

Recruiting EARLY_PHASE1
Jan 2021 — Mar 2021 [monthly]

Recruiting EARLY_PHASE1
Jun 2020 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1
Jan 2020 — Jun 2020 [monthly]

Recruiting EARLY_PHASE1

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States